On the other hand, studying the (dis)similarity between the molecular interplay induced by ACE inhibitors and other renin-angiotensin-system-acting drugs, such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, is critical for understanding whether these drugs directly benefit Alzheimer’s disease/dementia patients regardless of hypertension. This evidence concerns the gene ACE and hypertensive disorder.